Saltar al contenido principal

The Treatment of Myeloid Malignancies with Kinase Inhibitors, An Issue of Hematology/Oncology Clinics of North America

  • 1 Edición, Volumen 31-4 - 14 de julio de 2017
  • Última edición
  • Autor: Ann Mullally
  • Idioma: Inglés

This issue of Hematology/Oncology Clinics will focus on The Treatment of Myeloid Malignancies with Kinase Inhibitors. Articles will focus on: Targeting aberrant signaling in… Leer más

Descripción

This issue of Hematology/Oncology Clinics will focus on The Treatment of Myeloid Malignancies with Kinase Inhibitors. Articles will focus on: Targeting aberrant signaling in myeloid malignancies: promise versus reality; The development and use of imatinib for the treatment of chronic myelogenous leukemia; Mechanisms of resistance to ABL kinase inhibition in CML and the development of next generation ABL kinase inhibitors; Tyrosine kinase inhibitors in the treatment of systemic mastocytosis and hypereosinophilic syndrome; The development and use of JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPN); Mechanisms of resistance to JAK2 inhibitors in MPN; Kinase inhibitor screening in myeloid malignancies; and more!

Detalles del producto

  • Edición: 1
  • Última edición
  • Volumen: 31-4
  • Publicado: 14 de julio de 2017
  • Idioma: Inglés

Sobre el autor

AM

Ann Mullally

Afiliaciones y experiencia
Dana-Farber/Brigham and Women's Cancer Center